P F
1 mar, 2022
Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Effective 1 de mayo de 2022, the criteria used for medical necessity review of ExoDx Prostate IntelliScore (EPI) for Medicare Advantage Plans will be updated. Please refer to the draft medical policy for details here.